Context Therapeutics (CNTX) Retained Earnings (2020 - 2026)
Context Therapeutics (CNTX) posted Retained Earnings of -$139.6 million for Q1 2026, down 172.98% sequentially from $191.3 million in Q4 2025, and down 40.5% YoY from -$234.6 million in Q1 2025.
Context Therapeutics (CNTX) Retained Earnings (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Retained Earnings for 7 years, with the latest figure at -$139.6 million in Q1 2026.
- Quarterly Retained Earnings fell 40.5% year-over-year to -$139.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$139.6 million (down 40.5% YoY) and the FY2025 annual result came in at $191.3 million, up 0.7% from the prior year.
- Retained Earnings eased to -$139.6 million in Q1 2026 per CNTX's latest filing, from $191.3 million in the prior quarter.
- Over five years, Retained Earnings peaked at $191.3 million in Q4 2025 and troughed at -$139.6 million in Q1 2026.
- A 5-year average of $13.5 million and a median of -$40.5 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings slumped 164.56% in 2023, then soared 415.9% in 2024.
- Over 5 years, Retained Earnings stood at $78.8 million in 2022, then climbed by 1.37% to $79.9 million in 2023, then soared by 137.71% to $190.0 million in 2024, then climbed by 0.7% to $191.3 million in 2025, then sank by 172.98% to -$139.6 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$139.6 million, $191.3 million, and $191.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Context Therapeutics | 49.23 Mn | 49.23 Mn | - | 192.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.22 Mn |
| Mar 31, 2026 | -139.60 Mn |
| Dec 31, 2025 | 191.29 Mn |
| Sep 30, 2025 | 190.96 Mn |
| Jun 30, 2025 | -108.18 Mn |
| Mar 31, 2025 | -99.36 Mn |
| Dec 31, 2024 | 189.96 Mn |
| Sep 30, 2024 | -91.40 Mn |
| Jun 30, 2024 | 175.01 Mn |
| Mar 31, 2024 | -71.72 Mn |
| Dec 31, 2023 | 79.91 Mn |
| Sep 30, 2023 | -61.28 Mn |
| Jun 30, 2023 | -55.40 Mn |
| Mar 31, 2023 | -50.40 Mn |
| Dec 31, 2022 | 78.83 Mn |
| Sep 30, 2022 | -40.53 Mn |
| Jun 30, 2022 | -36.68 Mn |
| Mar 31, 2022 | 78.07 Mn |
| Dec 31, 2021 | 77.51 Mn |
| Sep 30, 2021 | -26.20 Mn |